A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/207824 |
Resumo: | Fenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect. |
id |
USP-31_3aa814150cbbf6acb7011ee4f16cac4d |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/207824 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complicationsDiabetic cardiomyopathyDiabetic retinopathyFenofibrateSphingolipidType 1 diabetic microvascular complicationsType 1 Diabetes mellitusFenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2023-02-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/20782410.1590/s2175-97902022e21332Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/207824/197328Copyright (c) 2022 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessVarghese, ResiaGopal Krishnamoorthy, Sadagoban Abdalla, Hassan Elrufae HassanBaiju, AiswaryaBorra, Swathi Swaroopa2023-08-18T20:02:26Zoai:revistas.usp.br:article/207824Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-08-18T20:02:26Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
title |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
spellingShingle |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications Varghese, Resia Diabetic cardiomyopathy Diabetic retinopathy Fenofibrate Sphingolipid Type 1 diabetic microvascular complications Type 1 Diabetes mellitus |
title_short |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
title_full |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
title_fullStr |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
title_full_unstemmed |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
title_sort |
A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications |
author |
Varghese, Resia |
author_facet |
Varghese, Resia Gopal Krishnamoorthy, Sadagoban Abdalla, Hassan Elrufae Hassan Baiju, Aiswarya Borra, Swathi Swaroopa |
author_role |
author |
author2 |
Gopal Krishnamoorthy, Sadagoban Abdalla, Hassan Elrufae Hassan Baiju, Aiswarya Borra, Swathi Swaroopa |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Varghese, Resia Gopal Krishnamoorthy, Sadagoban Abdalla, Hassan Elrufae Hassan Baiju, Aiswarya Borra, Swathi Swaroopa |
dc.subject.por.fl_str_mv |
Diabetic cardiomyopathy Diabetic retinopathy Fenofibrate Sphingolipid Type 1 diabetic microvascular complications Type 1 Diabetes mellitus |
topic |
Diabetic cardiomyopathy Diabetic retinopathy Fenofibrate Sphingolipid Type 1 diabetic microvascular complications Type 1 Diabetes mellitus |
description |
Fenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-02-07 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/207824 10.1590/s2175-97902022e21332 |
url |
https://www.revistas.usp.br/bjps/article/view/207824 |
identifier_str_mv |
10.1590/s2175-97902022e21332 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/207824/197328 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022) Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022) Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022) 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222917516066816 |